Ardelyx Inc ARDX

$3.31 -0.08 (-2.36%)

Valuation

Market cap
844,747,000
Revenue TTM
$407,320,000
Net income TTM
$-61,600,000
PE ratio
0.00
Forward PE
—
Profit margin
-15.12%
Debt to equity
1.69

Trading

Volume
5,818,200
Avg volume
4,491,164
Day's range
$3.23 – $3.41
Shares out
249,188,000
Stochastic %K
31%
Beta
0.68
Analysts
Strong Sell
Price target
$12.90

Price

Company profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, I...

Show more

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
510 745 1700
Website
https://www.ardelyx.com
Address
400 Fifth Avenue, Suite 210, Waltham, United States

Latest news

Stocktwits

findingthestock Oct 7, 2:31 PM
$ARDX one of the many lessons learned with investing in Ardelyx and bio pharma stocks is dillution, shares issued. CNBC had a headline about healthcare company GRAIL “As reported by CNBC, Jim Cramer says Grail’s stock can still rise” Grail (GRAL) trades at $134. It is unprofitable Compared it with Ardelyx who has more revenue the biggest different is dillution, shares issued and management Like many small cap pharma bio Ardelyx has issued a lot shares and has a lot of expenses It’s the reason why many look to get bought out and return shareholder value. Raab does not seem inclined to sell the company rather just keep growing organically. Mott has stopped buying. Stock price continues to decline, the company is not profitable. Having good products is one part of equation Q3 must be exceeding good with little negative or else the we are ALL DOOMED and stock will tank @crypto_biotech
0 replies
Kfled44 Oct 7, 2:27 PM
$ARDX has the gap finally been filled? Is it ok to go back up again? Asking for a friend
1 replies
FinDic Oct 7, 2:15 PM
$ARDX $SPY $QQQ $IWM $DJIA Serious question. Does anyone else have a stock with a massive dislocation between stock price and analyst prices? The average would be over a 300% gain but the stock seems to not be able to get out of its own way. Have not seen such disparity
1 replies
EthanStawk Oct 7, 2:15 PM
$ARDX Did my planned second entry to average down. The only question here is management, which is admittedly a large question, but the liquid cash position and revenue are solid. Might be a long hold and I'm prepared for a third buy should it hit my number, but if guess a turn around occurs after next earnings.
0 replies
smallfish78 Oct 7, 2:12 PM
$ARDX Another 10000 Jan 27 $4 puts today.
0 replies
FinDic Oct 7, 2:12 PM
$ARDX I hope something is cooking here
0 replies
knowinvest Oct 7, 2:11 PM
$ARDX hm, suddenly turned green, Mott buying?????
1 replies
Paul_Volcker Oct 7, 2:10 PM
$ARDX I hope a buyout happens here. I honestly don't want to have to listen to Mike Raab's voice anymore - that is kind of where I am at 👍
0 replies